| Literature DB >> 35807943 |
Juan F Garcia1, Soledad Arribalzaga2, Raquel Díez3, Cristina Lopez3, M Nelida Fernandez3, Juan J Garcia3, M Jose Diez3, Jesús Seco-Calvo2,4, Matilde Sierra3, Ana M Sahagún3.
Abstract
The use of supplements containing herbal active ingredients in sport has increased in recent years. Their consumption is explained by the benefits they may provide and because their natural origin do not involve health complications, from the point of view of the consumers. The aim of this study is to analyze the availability of four supplements (caffeine, turmeric, ginseng, cannabidiol) on the internet and understand the nature of these websites. A descriptive, observational, and cross-sectional study design was used. A detailed search was carried out with specifically developed software. The searches and data evaluation took 10 days. The websites consulted correspond to those that sell supplements, or some sport websites in the case of the Spanish ones, whereas those in English belong to pharmacies, parapharmacies, or herbalists. It is concluded that the websites do not provide adequate information to ensure proper consumption and lack advice on the choices of supplements and their administration guidelines.Entities:
Keywords: caffeine; cannabidiol; ginseng; internet availability; medicinal herbs; sport supplements; turmeric
Mesh:
Year: 2022 PMID: 35807943 PMCID: PMC9268717 DOI: 10.3390/nu14132764
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Characteristics of the websites reviewed.
| Search in Spanish | Search in English | Total | |
|---|---|---|---|
| Number of websites reviewed | 237 | 173 | 410 |
| Number of websites discarded | 27 | 38 | 65 |
| Number of websites included in the study | 210 | 135 | 345 |
| Number of websites selling the 4 products | 14 | 26 | 40 |
| Number of websites selling cannabidiol | 19 | 35 | 54 |
| Number of websites selling ginseng | 155 | 106 | 261 |
| Number of websites selling caffeine | 152 | 99 | 251 |
| Number of websites selling curcumin | 149 | 114 | 263 |
| Number of websites per type: | |||
They sell nutritional supplements | 45 | 19 | 64 |
|
Sports | 31 | 20 | 51 |
|
Supermarket | 28 | 26 | 54 |
|
Pharmacy | 37 | 11 | 48 |
|
Parapharmacy | 20 | 19 | 39 |
|
Laboratory | 12 | 17 | 29 |
|
Herbalist | 28 | 7 | 35 |
|
Websites that sell products of all kinds | 9 | 16 | 25 |
| Number of websites reporting on manufacturing laboratory | 58 | 59 | 117 |
| Number of websites with information on country of production | 18 | 25 | 43 |
| Number of websites reporting on ergogenic aids, | 66 | 18 | 84 |
| Number of websites reporting on the protocol administration | 115 | 83 | 198 |
| Number of websites reporting adverse reactions | 23 | 8 | 31 |
Characteristics of the offer for each compound in the websites reviewed.
| Cannabidiol | Ginseng | Caffeine | Curcumin | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spanish | English | Total | Spanish | English | Total | Spanish | English | Total | Spanish | English | Total | |
| Number of websites per type: | ||||||||||||
|
They sell nutritional supplements (they have a sports or sports nutrition section) | 5 | 7 | 12 | 18 | 15 | 33 | 22 | 18 | 40 | 39 | 15 | 54 |
|
Sports | 1 | 2 | 3 | 26 | 14 | 40 | 30 | 16 | 46 | 27 | 13 | 40 |
|
Supermarket | 0 | 4 | 4 | 22 | 20 | 42 | 26 | 20 | 46 | 24 | 25 | 49 |
|
Pharmacy | 3 | 11 | 14 | 31 | 10 | 41 | 28 | 8 | 36 | 32 | 9 | 41 |
|
Parapharmacy | 4 | 1 | 5 | 18 | 16 | 34 | 17 | 16 | 33 | 7 | 18 | 25 |
|
Laboratory | 0 | 1 | 1 | 8 | 13 | 21 | 6 | 10 | 16 | 4 | 15 | 19 |
|
Herbalist | 3 | 4 | 7 | 24 | 4 | 28 | 16 | 5 | 21 | 11 | 5 | 16 |
|
Websites that sell products of all kinds | 3 | 5 | 8 | 8 | 14 | 22 | 7 | 6 | 13 | 5 | 14 | 19 |
| Number of units sold | 95 | 739 | 834 | 4896 | 3694 | 8590 | 5699 | 3226 | 8925 | 2769 | 2866 | 5635 |
| Pharmaceutical forms | ||||||||||||
|
Capsules | 30 | 249 | 279 | 2455 | 1677 | 4132 | 2006 | 1045 | 3051 | 1728 | 1977 | 3705 |
|
Compressed tablets | 17 | 3 | 20 | 843 | 336 | 1179 | 686 | 237 | 923 | 447 | 250 | 697 |
|
Molding tablets | 0 | 1 | 1 | 261 | 279 | 540 | 206 | 172 | 378 | 94 | 144 | 238 |
|
Vials | 0 | 0 | 0 | 274 | 124 | 398 | 34 | 6 | 40 | 26 | 0 | 26 |
|
Blisters | 0 | 0 | 0 | 207 | 134 | 341 | 64 | 1 | 65 | 19 | 17 | 36 |
|
Sachets | 0 | 0 | 0 | 48 | 11 | 59 | 115 | 58 | 173 | 46 | 9 | 55 |
|
Solution | 0 | 10 | 10 | 164 | 278 | 442 | 50 | 18 | 68 | 156 | 14 | 170 |
|
Bars | 0 | 1 | 1 | 66 | 3 | 69 | 200 | 104 | 304 | 13 | 17 | 30 |
|
Drink | 14 | 6 | 20 | 79 | 163 | 242 | 150 | 177 | 327 | 0 | 10 | 10 |
|
Gel drink | 0 | 1 | 1 | 46 | 75 | 121 | 612 | 286 | 898 | 1 | 61 | 62 |
|
Gummies | 0 | 66 | 66 | 13 | 23 | 36 | 112 | 67 | 179 | 20 | 81 | 101 |
|
Powder | 0 | 8 | 8 | 211 | 234 | 445 | 1309 | 1002 | 2311 | 183 | 237 | 420 |
|
Root | 0 | 0 | 0 | 38 | 123 | 161 | 0 | 1 | 1 | 0 | 0 | 0 |
|
Cream | 4 | 36 | 40 | 16 | 25 | 41 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Oil/oily solution | 3 | 316 | 319 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 |
|
Tincture | 0 | 11 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 |
|
Infusion | 0 | 0 | 0 | 47 | 55 | 102 | 25 | 15 | 40 | 0 | 4 | 4 |
|
Chewing gum | 0 | 0 | 0 | 16 | 18 | 34 | 21 | 13 | 34 | 0 | 0 | 0 |
|
Seed | 0 | 0 | 0 | 9 | 16 | 25 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Oral drops | 25 | 25 | 50 | 40 | 32 | 72 | 18 | 12 | 30 | 8 | 18 | 26 |
|
Oral spray | 2 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
|
Others | 0 | 2 | 2 | 63 | 88 | 151 | 91 | 12 | 103 | 23 | 21 | 44 |
STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies.
| Item No. | Recommendation | Page No. | |
|---|---|---|---|
| Title and abstract | 1 | ( | 1 |
| ( | 1 | ||
|
| |||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 1–3 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 3 |
|
| |||
| Study design | 4 | Present key elements of study design early in the paper | 3 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 3 |
| Participants | 6 | ( | N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | N/A |
| Data sources/measurement | 8 * | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 3–4 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 3 |
| Study size | 10 | Explain how the study size was arrived at | N/A |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | N/A |
| Statistical methods | 12 | ( | N/A |
| ( | N/A | ||
| ( | N/A | ||
| ( | N/A | ||
| ( | N/A | ||
|
| |||
| Participants | 13 * | (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 4 lines 186–188 |
| (b) Give reasons for non-participation at each stage | 4 | ||
| (c) Consider use of a flow diagram | N/A | ||
| Descriptive data | 14 * | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | 5 |
| (b) Indicate number of participants with missing data for each variable of interest | N/A | ||
| Outcome data | 15 * | Report numbers of outcome events or summary measures | |
| Main results | 16 | ( | N/A |
| ( | N/A | ||
| ( | N/A | ||
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | N/A |
|
| |||
| Key results | 18 | Summarise key results with reference to study objectives | 10–11 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 8 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | N/A |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | N/A |
|
| |||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | The study was not funded |
* Give information separately for exposed and unexposed groups. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/ (accessed on 23 March 2022), Annals of Internal Medicine at http://www.annals.org/ (accessed on 23 March 2022), and Epidemiology at http://www.epidem.com/ (accessed on 23 March 2022). Information on the STROBE Initiative is available at www.strobe-statement.org (accessed on 5 June 2022).